(114) Evaluation of the Incidence and Management of Immune-Related Toxicities in Medical Oncology Patients

Poster Abstract:

Background: Immune checkpoint inhibitors (ICIs), a subset of cancer immunotherapy, augments the immune response against cancer cells. With increased activity of the immune system, side effects include autoimmune-like toxicities known as immune-related adverse events (irAEs). The incidence and prevalence of ICI-related toxicity is still being fully elucidated. Due to non-specific presentation of irAEs, the variety of organ systems involved, and inconsistent reporting, it is likely that reported rates underestimate the actual incidence of these events. The purpose of this study is to evaluate the incidence of irAEs in patients who received ICI therapy and to assess time to guideline recommended treatment.

Objective(s): The primary outcome of this study is quantifying the incidence of irAEs in patients receiving ICIs who required treatment at Baptist Hospital of Miami (BHM). Secondary outcomes include measuring time to treatment of irAEs from patient presentation, percentage of patients receiving appropriate therapeutic management by grade of toxicity, hospital length of stay, 30-day hospital readmission rate, and mortality during hospitalization.

Methods: This is a single-center, retrospective chart review of patients at least 18 years of age or older who presented to BHM, received an ICI between March 1, 2022 and June 30, 2023, and were treated for one of the pre-specified subset of ICD-10 codes denoting a potential irAE between July 1, 2022 and June 30, 2023. Patients were excluded if they received an ICI in combination with other oral or parenteral chemotherapy agents (excluding ICI-combination therapies), if they had a history of autoimmune disease prior to receiving an ICI, or if they were pregnant. Descriptive statistics will be utilized to report median, range, and frequency for each respective endpoint.

Results and Discussion/

Conclusions: The results and conclusions/discussion of this study are pending completion

References (must also be included in final poster): 1. Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clin Proc. 2019;94(7):1321-1329. doi:10.1016/j.mayocp.2019.03.012
2. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044-3060. Published 2022 Apr 24. doi:10.3390/curroncol29050247
3. Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;20(4):387-405. doi:10.6004/jnccn.2022.0020
4. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. Published 2017 Nov 21. doi:10.1186/s40425-017-0300-z
5. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315]. J Clin Oncol. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440
6. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy [published correction appears in Front Pharmacol. 2017 May 31;8:311]. Front Pharmacol. 2017;8:49. Published 2017 Feb 8. doi:10.3389/fphar.2017.00049
7. Chiu T, Yamamoto C, Niu F, et al. Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. Perm J. 2020;25:1. doi:10.7812/TPP/20.034
8. Puzanov I, Subramanian P, Yatsynovich YV, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis [published correction appears in J Immunother Cancer. 2021 Nov;9(11):]. J Immunother Cancer. 2021;9(6):e002553. doi:10.1136/jitc-2021-002553
9. Zhang C, Chen Z, Mo C, et al. Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study. Am J Cancer Res. 2021;11(12):6074-6085. Published 2021 Dec 15.
10. Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990-997. doi:10.1016/j.jaad.2018.10.062